{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:52:06Z","timestamp":1760575926611,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1053\/clon.2001.0026","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T09:54:50Z","timestamp":1032429290000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Royal College of Radiologists Annual Undergraduate Essay Prize Melanoma: the New Smallpox? Can Vaccines be Used to Treat Melanoma?"],"prefix":"10.1053","volume":"14","author":[{"given":"Gareth","family":"Forbes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/clon.2001.0026_RF1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/jnci\/84.18.1427","article-title":"Increasing incidence of cutaneous melanoma in Queensland, Australia","volume":"84","author":"MacLennan","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/clon.2001.0026_RF2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1440-0960.1999.00307.x","article-title":"Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now?","volume":"40","author":"Marks","year":"1999","journal-title":"Australas J Dermatol"},{"key":"10.1053\/clon.2001.0026_RF3","first-page":"326","article-title":"Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line","volume":"3","author":"Gross","year":"1943","journal-title":"Cancer Res"},{"key":"10.1053\/clon.2001.0026_RF4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4049\/jimmunol.91.5.604","article-title":"Immunity in hamsters to cells transformed in vitro among the papovaviruses","volume":"91","author":"Khera","year":"1963","journal-title":"J Immunol"},{"key":"10.1053\/clon.2001.0026_RF5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/bjc.1976.37","article-title":"A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin","volume":"33","author":"Hewitt","year":"1976","journal-title":"Br J Cancer"},{"key":"10.1053\/clon.2001.0026_RF6","first-page":"390","article-title":"The epidemiology of acquired immunodeficiency syndrome malignancies","volume":"27","author":"Goedert","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1053\/clon.2001.0026_RF7","first-page":"233","article-title":"Demonstration of antibodies against human malignant melanoma by immunofluorescence","volume":"64","author":"Morton","year":"1968","journal-title":"Surgery"},{"key":"10.1053\/clon.2001.0026_RF8","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1073\/pnas.80.17.5392","article-title":"Ganglioside GM2 as a human tumor antigen (OFA-I-1)","volume":"80","author":"Tai","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/clon.2001.0026_RF9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0065-230X(08)60295-X","article-title":"Toward a genetic analysis of tumor rejection antigens","volume":"58","author":"Boon","year":"1992","journal-title":"Adv Cancer Res"},{"key":"10.1053\/clon.2001.0026_RF10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s001099900042","article-title":"Human tumor antigens: implications for cancer vaccine development","volume":"77","author":"Wang","year":"1999","journal-title":"J Mol Med"},{"key":"10.1053\/clon.2001.0026_RF11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-9440(10)65321-7","article-title":"Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression","volume":"154","author":"Kageshita","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1053\/clon.2001.0026_RF12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1172\/JCI118958","article-title":"Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1\/Melan-A antigen","volume":"98","author":"Maeurer","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1053\/clon.2001.0026_RF13","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/9525","article-title":"Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients","volume":"5","author":"Lee","year":"1999","journal-title":"Nat Med"},{"key":"10.1053\/clon.2001.0026_RF14","first-page":"2571","article-title":"Immunoprevention of cancer: is the time ripe?","volume":"60","author":"Forni","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/clon.2001.0026_RF15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope spreading: lessons from autoimmune skin diseases","volume":"110","author":"Chan","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1053\/clon.2001.0026_RF16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1072-7515(98)00097-0","article-title":"Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase II, randomized, double blind, multicentre vaccinia melanoma oncolysate trial","volume":"187","author":"Wallack","year":"1998","journal-title":"J Am Coll Surg"},{"key":"10.1053\/clon.2001.0026_RF17","doi-asserted-by":"crossref","unstructured":"Mitchell, MS, Von Eschen, KB, Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proceedings of the Annual Meeting of the American Society of clinical Oncology, 1997, Abstract *1778.","DOI":"10.1097\/00008390-199706001-00179"},{"key":"10.1053\/clon.2001.0026_RF18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","article-title":"Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination GM2 ganglioside","volume":"12","author":"Livingston","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/clon.2001.0026_RF19","first-page":"874","article-title":"Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin +QS-21 vaccine: a dose-response study","volume":"6","author":"Chapman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1053\/clon.2001.0026_RF20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med"},{"key":"10.1053\/clon.2001.0026_RF21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655501900263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655501900263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:19:56Z","timestamp":1760541596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655501900263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0936655501900263"],"URL":"https:\/\/doi.org\/10.1053\/clon.2001.0026","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2002,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Royal College of Radiologists Annual Undergraduate Essay Prize Melanoma: the New Smallpox? Can Vaccines be Used to Treat Melanoma?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/clon.2001.0026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}